XTL Biopharma Settles with Social Proxy CEO & Shareholders
Ticker: XTLB · Form: 6-K · Filed: Nov 19, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: settlement, subsidiary, shares, warrants
TL;DR
XTL Bio settling with Social Proxy CEO/shareholders on ADSs & warrants - expect ownership adjustments.
AI Summary
XTL Biopharmaceuticals Ltd. filed a Form 6-K on November 19, 2024, detailing a settlement agreement entered into on November 11, 2024. This agreement involves the CEO of its subsidiary, The Social Proxy Ltd., and previous shareholders of Social Proxy, to adjust the number of American Depositary Shares (ADSs) and warrants to be issued.
Why It Matters
This settlement could impact the ownership structure and potential dilution for XTL Biopharmaceuticals' shareholders by adjusting the issuance of ADSs and warrants.
Risk Assessment
Risk Level: medium — The settlement involves adjustments to share issuances, which can introduce uncertainty and potential dilution for existing shareholders.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Filer of the 6-K report
- The Social Proxy Ltd. (company) — Wholly owned subsidiary of XTL Biopharmaceuticals
- November 11, 2024 (date) — Date the settlement agreement was entered into
- November 19, 2024 (date) — Filing date of the 6-K report
FAQ
What is the specific adjustment to the number of American Depositary Shares (ADSs) and warrants?
The filing states that the settlement is to 'adjust the number of American Depositary Shares (“ADSs”) and warrants issuable', but does not provide specific figures for this adjustment.
Who are the previous shareholders of The Social Proxy Ltd. involved in the settlement?
The filing refers to them as 'the previous shareholders of the Social Proxy', but does not name them specifically.
What was the reason for the settlement agreement?
The filing indicates the settlement was to 'adjust the number of American Depositary Shares (“ADSs”) and warrants issuable', suggesting a dispute or renegotiation regarding these issuances.
Does this settlement affect XTL Biopharmaceuticals' other subsidiaries?
The settlement specifically names the CEO of XTL's wholly owned subsidiary, The Social Proxy Ltd., and its previous shareholders, implying the impact is primarily related to this subsidiary.
Is XTL Biopharmaceuticals filing an annual report on Form 20-F?
Yes, the filing indicates with a checkmark that the registrant files annual reports under Form 20-F.
Filing Stats: 784 words · 3 min read · ~3 pages · Grade level 15.7 · Accepted 2024-11-19 17:30:04
Filing Documents
- ea0221906-6k_xtlbio.htm (6-K) — 16KB
- 0001213900-24-100258.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 19, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 2